Predicting Tumor Response to PD-1 Blockade

N Engl J Med. 2019 Aug 1;381(5):477-479. doi: 10.1056/NEJMcibr1906340.

Authors

Li Ding¹, Feng Chen¹

Affiliation

¹ From the Department of Medicine (L.D., F.C.), McDonnell Genome Institute (L.D.), the Department of Genetics (L.D.), Siteman Cancer Center (L.D., F.C.), and the Department of Cell Biology and Physiology (F.C.) - all at Washington University School of Medicine, St. Louis.

PMID: 31365807
DOI: 10.1056/NEJMcibr1906340

No abstract available

MeSH terms

Animals
Antineoplastic Agents, Immunological / therapeutic use
DNA Mismatch Repair*
Disease Models, Animal
Humans
Immunotherapy*
Lymphocyte Activation
Mice
Microsatellite Instability*
Mutation*
Neoplasms / drug therapy*
Neoplasms / genetics
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
T-Lymphocytes / immunology
Tumor Burden / drug effects

Substances

Antineoplastic Agents, Immunological
Programmed Cell Death 1 Receptor